8.80
+0.39(+4.64%)
Currency In USD
| Previous Close | 8.41 |
| Open | 8.56 |
| Day High | 8.84 |
| Day Low | 8.3 |
| 52-Week High | 14.47 |
| 52-Week Low | 7.78 |
| Volume | 45,992 |
| Average Volume | 80,349 |
| Market Cap | 121.82M |
| PE | -6.03 |
| EPS | -1.46 |
| Moving Average 50 Days | 9.31 |
| Moving Average 200 Days | 10.3 |
| Change | 0.39 |
If you invested $1000 in Greenwich LifeSciences, Inc. (GLSI) since IPO date, it would be worth $1,760 as of December 05, 2025 at a share price of $8.8. Whereas If you bought $1000 worth of Greenwich LifeSciences, Inc. (GLSI) shares 3 years ago, it would be worth $655.25 as of December 05, 2025 at a share price of $8.8.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date
GlobeNewswire Inc.
Dec 03, 2025 11:00 AM GMT
STAFFORD, Texas, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immuno
Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial
GlobeNewswire Inc.
Oct 09, 2025 10:00 AM GMT
STAFFORD, Texas, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immuno
Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium
GlobeNewswire Inc.
Oct 02, 2025 10:00 AM GMT
STAFFORD, Texas, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immuno